Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
about
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognitionABL tyrosine kinases: evolution of function, regulation, and specificityc-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseAllosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocyclesMolecular mechanisms for survival regulation of chronic myeloid leukemia stem cellsTen things you should know about protein kinases: IUPHAR Review 14Targeting cancer with kinase inhibitorsThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaAbl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and MotilityTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassMechanisms of drug resistance in kinases.The function of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P-binding siteRole of ABL family kinases in cancer: from leukaemia to solid tumoursAllosteric interactions between the myristate- and ATP-site of the Abl kinaseIdentification of small molecules that disrupt signaling between ABL and its positive regulator RIN1Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase FunctionDefying c-Abl signaling circuits through small allosteric compounds.NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors.Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitorsThe Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.Activation state-selective kinase inhibitor assay based on ion mobility-mass spectrometryMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Insights into protein kinase regulation and inhibition by large scale structural comparisonDetection of secondary binding sites in proteins using fragment screeningComputational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.The energy landscape analysis of cancer mutations in protein kinasesEmerging drugs for chronic myeloid leukemia.Assay development and high-throughput screening of small molecular c-Abl kinase activators.Small molecule probes of cellular pathways and networks.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Myristoylation and membrane binding regulate c-Src stability and kinase activityImaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scatteringAllosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315IOvercoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
P2860
Q24297748-1B4908DC-1823-4309-B419-5ACBBC54A7C0Q24299738-AAA1227E-C880-4F74-B3CB-D1BC10B7740BQ24318974-39C130FC-0142-4B1A-A31E-8CD17C570205Q24321968-A681B08E-5FC8-4158-9497-AF7981F981CEQ24614202-1CFFFFEC-A493-4410-9AA1-F4769F0AFE6DQ26828528-501C8B77-7F2E-4330-8829-D2DD86D21AB3Q26849417-98C43939-7E43-4CCA-B0E9-572891C7BBB5Q26865765-C4D3B2F5-9EE8-401C-9474-626CC7D702B8Q26866312-EBA41263-40F2-4FF4-9D9C-1375AF486468Q27025242-87E19904-B776-4D55-9A2A-8070F3A69154Q27308835-B0C30EEF-34E4-4DFB-86F9-37A43F8E27D6Q27658951-3BB09983-62CF-4EC9-9F02-A87D3DF1850FQ27667290-9C9CFFF2-13BC-463D-B7D5-F3A1A6080F97Q27692567-423673E7-5CD6-49A7-8DF7-3D32CED41E09Q28115841-3E731383-44B1-4310-B012-D4E5D1F939C4Q28396643-926238E6-79AE-405B-BAC4-F2E955798009Q28476718-C50758D6-D0A7-4166-B0E0-FCC55DF184A3Q28545055-A93B01B3-FF9D-4912-B8EF-D7E7DFA3C473Q28546849-838079D8-8838-4828-99B5-C8A2AB35B215Q30009269-3A57C343-7845-4387-8BD9-F6931309EF94Q30009530-E13C45B5-271B-4E65-B2D8-0AA1A5D1B435Q30009947-9080F55C-11C7-44E8-8653-7E80E0D27EBEQ30158039-D3529044-7C9F-473F-854C-D1CC36CD0966Q30352015-56A06C8D-A270-412A-8AE4-83F956761FEFQ30374671-3625954F-FF8B-4326-B159-273B58B81096Q30381908-FE80004A-71FA-4550-8E13-55ABE6A18567Q30382347-B7092540-E124-485E-8FBF-A8925D6A31DBQ31036423-FADBB8EC-DB67-49C2-B250-AD9D1B4FDDFCQ31038185-B0236B64-0816-4891-8DBD-6BA06A9484FFQ33536762-57BC9A63-AA1D-4116-9566-A97F14378164Q33715301-3942E07C-078A-4294-BD3D-C4709819DA87Q33750619-F31AC34B-2BBC-4A84-A502-3BBD81F80029Q33890786-77EB0AD1-DED9-4529-A0D6-D2D1507418ABQ34052015-2239A7D3-A08C-4D1A-90EF-898888000EFCQ34065882-D2A999D9-F08A-4D52-9CD6-3429C039506CQ34119774-B79778EE-21BD-4494-B46C-4DD415CA02FFQ34384711-42AF8FA0-EC52-40F9-A19B-A2DDB7BECF7BQ34416737-24318123-AC86-4DB7-9FF2-A72E8A01234FQ34481459-A0A0EAA0-D0B7-418F-BD11-59D8A160C5BCQ34491764-E79742BD-5D5B-41F9-A2D3-99FE9136EFBD
P2860
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@ast
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@en
type
label
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@ast
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@en
prefLabel
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@ast
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@en
P2093
P356
P1476
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
@en
P2093
Anastasia Velentza
Christine Sloan
Doriano Fabbro
Francisco J Adrián
Guobao Zhang
Jürgen Mestan
Nathanael S Gray
Paul Manley
Qiang Ding
Sheng Ding
P2888
P304
P356
10.1038/NCHEMBIO760
P577
2006-01-15T00:00:00Z